A New Fibromyalgia Drug Deal Reaches 21 Million More Medicare Lives. Her Own Plan Could Still Decide What She Pays

Imagine a retired teacher in her late 60s who has lived with fibromyalgia for years. She has cycled through drugs that never quite worked. She is a hypothetical patient, but her question is a common one. This fall she learns a new fibromyalgia drug just reached 21 million more Medicare lives, and she figures her copay is settled.

That conclusion is premature. On September 22, 2026, Tonix Pharmaceuticals (NASDAQ: TNXP) announced a second major managed Medicare payer agreement for TONMYA. Those 21 million newly covered Medicare members bolstered the drug’s total Medicare reach to 32 million, according to Tonix. The U.S. Food and Drug Administration (FDA) approved TONMYA for fibromyalgia in adults on August 15, 2025, and Tonix calls it the first new prescription medicine approved for the condition in more than 15 years.

If you take TONMYA, or your doctor has brought it up, and your drug coverage comes from a stand-alone Part D plan or a Medicare Advantage plan, one document will shape what you pay far more than this deal will.

Why 21 Million Covered Lives Won’t Set Her Copay

“Covered lives” is the payer industry’s headcount. It counts every member of every plan an agreement reaches, across many plan designs and regions. Each Part D or Medicare Advantage drug plan still picks the drug’s tier and sets what members pay at the pharmacy counter.

That choice lives in her plan’s formulary, the list of covered drugs and the tier assigned to each one. Two neighbors with plans from the same insurer can get different terms for the same prescription. Tonix did not name the payer, so she can’t even be sure her own insurer signed on.

Covered Drugs Can Still Come With Costly Hurdles

A drug can be covered and still be expensive or slow to get. Four plan tools decide how it goes:

• Tier placement. Lower tiers usually charge a flat copay. Higher tiers often charge coinsurance, a share of the plan’s negotiated pharmacy price, so a covered drug can still carry a steep bill.
• Prior authorization. Her doctor has to justify the prescription before the plan will pay.
• Quantity limits. The plan caps how many tablets it covers per fill.
• Step therapy. She may have to try an older, cheaper drug first.

Plans can make certain changes during the year, but they must follow Medicare’s formulary-change rules and notify affected members. A plan that looks fine in December can look different by spring.

She should also raise one clinical point with her doctor. TONMYA’s prescribing information says its clinical trials did not include enough patients 65 and older to tell whether they respond differently from younger adults.

2027 Makes Her Full-Year Cost the Number That Counts

The Centers for Medicare & Medicaid Services (CMS) caps Part D out-of-pocket spending at $2,100 in 2026, and the cap rises to $2,400 in 2027. If her Part D plan covers TONMYA, what she pays for it counts toward that cap, along with her other covered drugs. Once she hits the cap, she pays nothing more for covered Part D drugs for the rest of the year.

That changes the question she should be asking. A high coinsurance tier could push her to the cap within the first few months. A drug her plan leaves off the formulary generally doesn’t count toward the cap at all, so she could pay the full price with no limit. The cap leaves premiums untouched. She still owes her Part D premium and the separate Part B premium, which is $202.90 a month in 2026 and doesn’t cover TONMYA. Income-related surcharges and gaps in coverage can push her total bill higher (as we explain in our free guide, Medicare’s Hidden Bills).

Tonix’s Medicare agreement can’t tell her what she’ll spend over the year. That total depends on her tier, her other prescriptions and when she fills them.

Run Plan Finder With TONMYA Before December 7

Open enrollment runs October 15 through December 7, 2026. If her current plan is still offered, she generally stays enrolled automatically, with next year’s costs and coverage. She should review both its Annual Notice of Change and its 2027 formulary.

1. Enter TONMYA and every other prescription, with exact doses, into Medicare’s Plan Finder on Medicare.gov.
2. Sort plans by total estimated annual drug cost, meaning premium plus cost sharing, instead of premium alone.
3. Open each finalist to check TONMYA’s tier, any prior authorization, step therapy or quantity limits, and which pharmacies get preferred pricing.
4. Call the plan to confirm before enrolling.

If her plan puts TONMYA out of reach, her doctor can make the case for covering it or lifting a restriction through a formulary exception. If the sticking point is price, a separate request called a tiering exception could lower her share of the bill, if her plan allows it.

The new agreement gives her a reason to look. It doesn’t tell her what she’ll owe. Before December 7, she needs to find out what TONMYA will cost under the plan she’s counting on for 2027.

Contact [email protected] for any questions or corrections.